Cadonilimab plus eribulin vs eribulin alone for triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether combining the immunotherapy drug cadonilimab with the chemotherapy eribulin works better than eribulin alone for people with recurrent or metastatic triple-negative breast cancer. It aims to see if the combination can shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- You must have triple-negative breast cancer that has come back or spread and cannot be cured.
- You can have had up to 2 prior treatments for advanced disease, including at least one with an anthracycline and one with a taxane.
- You need to have at least one measurable tumor that can be seen on scans.
- You must agree to provide a tumor sample (from a past biopsy or a new one) to check for PD-L1 protein.
- You must have good organ function (kidneys, liver, blood counts) and be healthy enough for treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (cadonilimab) plus chemotherapy for people with advanced triple-negative breast cancer that has come back or spread. It aims to see if the combination works better than standard treatment.
This trial tests a new combination of three drugs (camrelizumab, apatinib, and eribulin) against the standard chemotherapy chosen by your doctor. It's for people with advanced triple-negative breast cancer that has gotten worse after previous treatments.
This trial tests a combination of a PD-L1 antibody (a type of immunotherapy) with a low-dose, continuous chemotherapy regimen called VEX for advanced triple-negative breast cancer that has spread to other parts of the body. It may be an option if you have had only one prior chemotherapy for metastatic disease and have already been treated with certain common chemo drugs.
This study tests a new drug called JSKN016 against standard chemotherapy options for triple-negative breast cancer that has stopped responding to previous treatments. The trial aims to find out if JSKN016 works better or offers other benefits for patients like you.
This trial tests whether adding trilaciclib to the chemotherapy drug eribulin can protect bone marrow and improve outcomes in people with advanced triple-negative breast cancer who have already tried at least two other chemotherapies.
This trial tests a combination of two drugs, inavolisib and eribulin, for people with advanced triple-negative breast cancer that has a specific genetic change called a PIK3CA mutation. The goal is to see if the combination works better than standard treatments.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.